SDG&E establece nuevos objetivos y acelera las acciones para lograr emisiones netas cero de GEI para 2045

2 years ago0 Comments4721 Min Read

SAN DIEGO–(BUSINESS WIRE)–La compañía de San Diego Gas & Electric (SDG&E) hoy publicó su informe anual de progreso de sostenibilidad, que destaca lo que la compañía ha logrado durante el año pasado para ayudar a crear un futuro limpio, resiliente y equitativo. El informe también detalla objetivos nuevos y acelerados para ayudar a cumplir su compromiso de alcanzar cero emisiones netas de gases de efecto invernadero para 2045. “Durante el año pasado, pasamos mucho tiempo escuchando a un

SDG&E establece nuevos objetivos y acelera las acciones para lograr emisiones netas cero de GEI para 2045

Leave a Reply Cancel reply

Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice

TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice

TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice

TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

SDG&E establece nuevos objetivos y acelera las acciones para lograr emisiones netas cero de GEI para 2045

Leave a Reply Cancel reply

Artículos Relacionados